HL
NBIX icon

Harding Loevner’s Neurocrine Biosciences NBIX Stock Holding History

Harding Loevner’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-767
Closed -$81K – 133
2022
Q3 		$81K Sell
767
-43
-5% -$4.36K ﹤0.01% 90
2022
Q2 		$79K Hold
810
– – ﹤0.01% 90
2022
Q1 		$61K Buy
810
+33
+4% +$2.8K ﹤0.01% 95
2021
Q4 		$66K Buy
777
+215
+38% +$19.8K ﹤0.01% 102
2021
Q3 		$54K Hold
562
– – ﹤0.01% 99
2021
Q2 		$55K Hold
562
– – ﹤0.01% 105
2021
Q1 		$55K Hold
562
– – ﹤0.01% 110
2020
Q4 		$54K Hold
562
– – ﹤0.01% 106
2020
Q3 		$54K Buy
562
+306
+120% +$35.4K ﹤0.01% 137
2020
Q2 		$31K Hold
256
– – ﹤0.01% 117
2020
Q1 		$22K Buy
+256
New +$25.1K ﹤0.01% 121

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return